Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lars Bauer

Showing results (11-20 of 47) with videos related to

Pageof 5
Sort By:
Clinical Neuropharmacology|February 17, 2016
The Efficacy Profile of Rotigotine During the Waking Hours in Patients With Advanced Parkinson's Disease: A Post Hoc AnalysisPeter A LeWitt, Werner Poewe, Lawrence W Elmer, et al.
Expert Opinion on Pharmacotherapy|December 22, 2012
Safety and efficacy of rotigotine transdermal patch in patients with restless legs syndrome: a post-hoc analysis of patients taking 1 - 3 mg/24 h for up to 5 yearsElisabeth Dohin, Birgit Högl, Luigi Ferini-Strambi, et al.
Clinical Therapeutics|August 13, 2018
Pharmacokinetics, Tolerability, and Bioequivalence of Two Formulations of Rotigotine in Healthy Chinese SubjectsYun Liu, Brian Tomlinson, Jiyuan Guo, et al.
Journal of Clinical Pharmacology|December 3, 2015
A Randomized Controlled Exploratory Pilot Study to Evaluate the Effect of Rotigotine Transdermal Patch on Parkinson's Disease-Associated Chronic PainOlivier Rascol, Theresa Zesiewicz, K Ray Chaudhuri, et al.
RMD Open|September 4, 2024
Comparison of established and preliminarily proposed ASAS MRI working group cut-offs for inflammatory MRI lesions in the sacroiliac joints in radiographic and non-radiographic axial spondyloarthritisXenofon Baraliakos, Pedro M Machado, Lars Bauer, et al.
Expert Review of Neurotherapeutics|May 27, 2017
Switching from an oral dopamine receptor agonist to rotigotine transdermal patch: a review of clinical data with a focus on patient perspectiveSun Ju Chung, Mahnaz Asgharnejad, Lars Bauer, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 30, 2005
Discrepancies in the interpretation of clinical symptoms and signs in the diagnosis of multiple sclerosis. A proposal for standardizationBernard M J Uitdehaag, Ludwig Kappos, Lars Bauer, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|February 28, 2018
An observational study of rotigotine transdermal patch and other currently prescribed therapies in patients with Parkinson's diseaseThomas Müller, Eduardo Tolosa, Letitia Badea, et al.
Postgraduate Medicine|November 25, 2016
Patients' perception of Parkinson's disease-associated pain following initiation of rotigotine: a multicenter non-interventional studyLars Timmermann, Christian Oehlwein, Gerhard Ransmayr, et al.
Journal of Parkinson'S Disease|March 20, 2014
A randomized study of rotigotine dose response on 'off' time in advanced Parkinson's diseaseAnthony P Nicholas, Rupam Borgohain, Pedro Chaná, et al.
Pageof 5

Showing results (11-20 of 47) with videos related to

Sort By:
Pageof 5
Clinical Neuropharmacology|February 17, 2016
The Efficacy Profile of Rotigotine During the Waking Hours in Patients With Advanced Parkinson's Disease: A Post Hoc AnalysisPeter A LeWitt, Werner Poewe, Lawrence W Elmer, et al.
Expert Opinion on Pharmacotherapy|December 22, 2012
Safety and efficacy of rotigotine transdermal patch in patients with restless legs syndrome: a post-hoc analysis of patients taking 1 - 3 mg/24 h for up to 5 yearsElisabeth Dohin, Birgit Högl, Luigi Ferini-Strambi, et al.
Clinical Therapeutics|August 13, 2018
Pharmacokinetics, Tolerability, and Bioequivalence of Two Formulations of Rotigotine in Healthy Chinese SubjectsYun Liu, Brian Tomlinson, Jiyuan Guo, et al.
Journal of Clinical Pharmacology|December 3, 2015
A Randomized Controlled Exploratory Pilot Study to Evaluate the Effect of Rotigotine Transdermal Patch on Parkinson's Disease-Associated Chronic PainOlivier Rascol, Theresa Zesiewicz, K Ray Chaudhuri, et al.
RMD Open|September 4, 2024
Comparison of established and preliminarily proposed ASAS MRI working group cut-offs for inflammatory MRI lesions in the sacroiliac joints in radiographic and non-radiographic axial spondyloarthritisXenofon Baraliakos, Pedro M Machado, Lars Bauer, et al.
Expert Review of Neurotherapeutics|May 27, 2017
Switching from an oral dopamine receptor agonist to rotigotine transdermal patch: a review of clinical data with a focus on patient perspectiveSun Ju Chung, Mahnaz Asgharnejad, Lars Bauer, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 30, 2005
Discrepancies in the interpretation of clinical symptoms and signs in the diagnosis of multiple sclerosis. A proposal for standardizationBernard M J Uitdehaag, Ludwig Kappos, Lars Bauer, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|February 28, 2018
An observational study of rotigotine transdermal patch and other currently prescribed therapies in patients with Parkinson's diseaseThomas Müller, Eduardo Tolosa, Letitia Badea, et al.
Postgraduate Medicine|November 25, 2016
Patients' perception of Parkinson's disease-associated pain following initiation of rotigotine: a multicenter non-interventional studyLars Timmermann, Christian Oehlwein, Gerhard Ransmayr, et al.
Journal of Parkinson'S Disease|March 20, 2014
A randomized study of rotigotine dose response on 'off' time in advanced Parkinson's diseaseAnthony P Nicholas, Rupam Borgohain, Pedro Chaná, et al.
Pageof 5